FDAnews
www.fdanews.com/articles/81494-clinical-data-on-factive-tablets-presented

CLINICAL DATA ON FACTIVE TABLETS PRESENTED

October 7, 2005

At the 43rd Annual Meeting of the Infectious Diseases Society of America, Oscient Pharmaceuticals will present clinical data on its fluoroquinolone antibiotic, Factive (gemifloxacin mesylate) tablets.

Data was obtained from a Phase III program studying Factive for the potential treatment of acute bacterial sinusitis (ABS). The data are based on a meta-analysis of four pooled Phase III studies, and examined the efficacy of Factive in treating ABS in a specific sub-population of patients with allergic rhinitis. The retrospective analysis determined that Factive, compared to the other drugs studied (cefuroxime and trovafloxacin), was more effective in treating ABS in patients with allergic rhinitis.